The Oxford Science Park

Find Out The Latest

Welcome to the latest news from The Oxford Science Park, where you can keep up to date with developments across our community. From company milestones and scientific breakthroughs to investment news, partnerships, events and Park announcements, discover how our occupiers are advancing innovation and shaping the future.

Media enquiries: comms@oxfordsp.com

New CEO for Oxford Nanopore Technologies

09 Dec 2025

Oxford Nanopore Technologies has announced the appointment of Francis Van Parys as Chief Executive Officer. Francis will join the company and the Board as an Executive Director on 2 March 2026. Francis brings more than 20 years of experience leading multi-billion-dollar life science businesses, with a strong track record of scaling innovation-driven organisations through commercial and operational excellence. He is currently President and CEO... Read more

Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity

13 Nov 2025

Scripta Therapeutics, based at The Oxford Science Park, has emerged from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science... Read more

Enara Bio announces discovery of new cancer specific dark antigen

06 Nov 2025

Enara Bio has identified a new cancer-specific marker, called DARKFOX, that the company says could broaden the reach of next-generation immunotherapies for solid tumours. DARKFOX is a protein fragment displayed on the surface of many solid tumour cells - including most lung, head and neck, and oesophageal squamous cell cancers - while appearing at very low levels in healthy tissue. According to Enara, this combination of broad tumour coverage... Read more

Theolytics appoints new Chief Medical Officer

08 Oct 2025

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulatory activities for Theolytics, including for its lead asset THEO-260, which is being investigated in UK and US trials evaluating two different routes of administration (IV and IP, respectively) in... Read more

Sitryx receives FDA clearance to progress trials of oral treatment of atopic dermatitis

03 Oct 2025

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for SYX-5219, to support the initiation of a Phase 1b trial in adults with moderate to severe atopic dermatitis in the United States. The Company expects to... Read more

News